Clarity Pharmaceuticals: Receives $3.26m R&D refund

Clarity Pharmaceuticals Receives $3.26m R&D refund

• Clarity Pharmaceuticals (CU6) has received a research and development (R&D) tax refund of more than $3.26 million for FY21
• The refund is part of The Australian Federal Government’s R&D tax incentive, recognising the R&D undertaken by Clarity in the radiopharmaceutical field
• The R&D tax incentive is a program by the Australian Federal Government the encourages companies to engage and invest in R&D activities
• Clarity will use the $3.26 million to further finance the development of its Targeted Copper Theranostics (TCT) platform of products for various cancer indications
• Shares in Clarity are trading up 2.84 per cent to 72.5 cents